Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: IND Enabling Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 21, 2021
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Idronoxil
Therapeutic Area: Oncology Product Name: Veyonda
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2021
IND granted by FDA on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy. The Company has a patent application currently under examination that relates to use of idronoxil in combination with various chemotherapy drugs.